medigraphic.com
ISSN 2077-2874 (Electronic)
EDUMECENTRO. Revista Educación Médica del Centro

2022, Number 1

<< Back Next >>

EduMeCentro 2022; 14 (1)

Social impact of antiphospholipid syndrome: its impact on the quality of life of patients

Pérez de Alejo RMM, Pérez de Alejo RAJ, Jiménez DLJ, Mérida LFR

Language: Spanish
References: 29
Page:
PDF size: 160.95 Kb.


ABSTRACT

Introduction: antiphospholipid syndrome is a rare, autoimmune, thrombophilic disease, still little known to all health professionals, which implies delay in diagnosis and timely treatment.
Objective: to expose the factors of social impact of the antiphospholipid syndrome due to its incidence in the quality of life of the patients.
Methods: the review of the bibliography was carried out through the Google Scholar search engine with the descriptors: antiphospholipid syndrome, morbidity and mortality, damage, social impact, quality of life, in the SciELO, Medline-Pubmed, and Hinari databases.
Results: the review focuses on four subtopics: Occurrence of antiphospholipid syndrome in thrombotic and obstetric morbidity and mortality, Recurrence of thrombotic events and accumulated chronic damage, Impairment of quality of life in patients with antiphospholipid syndrome, and Importance of Educational work on the social impact of antiphospholipid syndrome. Changes in lifestyles to correct the risk factors that these patients must face, add restrictions to their daily life and the fear of recurrences and death, cause additional psychological alterations that motivate specialized care.
Conclusions: it is necessary to design large-scale health strategies for the comprehensive and multidisciplinary care of patients with antiphospholipid syndrome, which include training health professionals and applying educational actions that involve families.


REFERENCES

  1. Gaspar al. PGe. The assessment of patients with the antiphospholipid antibody syndrome: where are we now? Rheumatology [internet]. 2020 [citado 26/05/2022];59:[aprox. 7 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32359070/

  2. Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A. Epidemiology of Antiphospholipid Syndrome in the General Population. Curr Rheumatol Rep [internet]. 2022 [citado 02/02/2022];23(12):85. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34985614/

  3. Llaguno de Mora RI, Loján Córdova MC, Lema Barahona AJ, Castillo Jumbo EP, Flores Acosta MJ. Manejo del síndrome antifosfolipídico primario en el embarazo. Correo Científico Médico (CCM) [internet]. 2020 [citado 02/02/2022];24(4):[aprox. 9 p.]. Disponible en: https://www.medigraphic.com/pdfs/correo/ccm-2020/ccm204o.pdf

  4. Rahman A. Management of antiphospholipid syndrome. Clinical Rheumatology [internet]. 2020 [citado 02/02/2022];39:[aprox. 9 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32458245/

  5. Hernández Valverde A, Arias Vargas R, Miranda Vargas L. Diagnóstico y manejo del síndrome antifosfolípidocatastrófico. Revista Médica Sinergia [internet]. 2020 [citado 02/02/2022];5(3):[aprox. 9 p.]. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/394

  6. Rodziewicz M, D'Cruz DP. An update on the management of antiphospholipid syndrome. Ther Adv Musculoskel Dis [internet]. 2020 [citado 02/02/2022];12:[aprox. 10 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32523633/

  7. Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, et al. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus [internet]. 2020 [citado 18/03/2022];29(12):[aprox 22 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33100166/

  8. Tektonidou MG. Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Front Immunol [internet]. 2018 [citado 27/01/2022];9:1181. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29904380/

  9. Loraine LL. Enfermedades cronicas y vida cotidiana. Rev Cubana Salud Publica [internet]. 2011 [citado 18/03/2022];37(4):[aprox. 11 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662011000400013

  10. Falcón Fariñas IN, Nordelo Valdivia A, Campal Espinosa AC. Metodología de evaluación de impacto social para programa de salud. Humanidades Médicas [internet]. 2018 [citado 18/03/2022];18(1):[aprox. 14 p.]. Disponible en: http://scielo.sld.cu/pdf/hmc/v18n1/hmc07118.pdf

  11. 11 .Limper MC, Talarico R. Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open Published Online [internet]. 2018 [citado 18/03/2022];4(Suppl 1):e000785. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30402272/

  12. Radin M, Barinotti A, Cecchi I, Rubini E, Sciascia S, Roccatello D. Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation. Orphanet J Rare Dis [internet]. 2021 [citado 18/03/2022];16: [aprox. 9 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34134750/

  13. Ashorobi D, Atif Ameer M, Fernandez R. Thrombosis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK538430/

  14. Lugones Botell M, Ramírez Bermúdez M, López JI. Síndrome antifosfolipídico. Algunos aspectos de interés para nuestra especialidad. Rev Cubana Obstet Ginecol [internet]. 2006 [citado 18/03/2022];32(3): [aprox. 11 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-600X2006000300004

  15. Cortés Guerrieri V. Accidente cerebrovascular y síndrome antifosfolípido. Hematología [internet]. 2019 [citado 18/03/2022];22(15): [aprox. 6 p.]. Disponible en: https://netmd.org/hematologia/hematologia-articulos/accidente-cerebrovascular-y-sindrome-antifosfolipido

  16. Calcaterra I, Tufano A, Lupoli R, Iannuzzo G, Emmi G, Di Minno MND. Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat? Polish Archives of Internal Med [internet]. 2021[citado 22/01/2022];131(2): [aprox. 10 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32491304/

  17. Pires da Rosa GG, Cervera R. Non criteria manifestations of antiphosfholipid syndrome: An overwiew. Span J Med [internet]. 2021 [citado 22/01/2022];1(2):[aprox. 8 p.]. Disponible en: https://www.spanishjmed.com/frame_esp.php?id=38

  18. Uludag G, Onghanseng N, Tran AN, Hassan M, Sohail Halim M, Sepah YJ, et al. Current concepts in the diagnosis and management of antiphospholipid syndrome and ocular manifestations. J Ophthalmic Inflamm Infect [internet] 2021 [citado 21/01/2022];11(1):[aprox. 11 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33834305/

  19. Ghembaza AD. Management of Antiphospholipid Syndrome. Biomedicines [internet]. 2020 [citado 22/01/2022];8(508):[aprox. 10 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25228720/

  20. Belmar Vega L. Non-Criteria Antiphospholipid Antibodies: Risk Factors for Endothelial Dysfunction in Women with Pre-Eclampsia. Life (Basel) [internet]. 2020 [citado 21/01/2021];10(10): [aprox. 6 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33066645/

  21. Calcaterra I, Tufano A, Lupoli R, Iannuzzo G, Emmi G, Di Minno MND. Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat? Polish Arch Internal Med [internet]. 2021 [citado 18/03/2022];131(2): [aprox. 10 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32491304/

  22. Mériem Belhocine LC, Martin Silva N, Morel N, Guettrot-Imbert G, Paule R, Le Jeunne C. Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women. Arthritis Research & Therapy [internet]. 2018 [citado 18/03/2022]; 20(1): [aprox. 6 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30400982/

  23. de Oliveira Rodrigues V, de Góes A, Silva Soligo E, Duque Pannain G. Antiphospholipid Antibody Syndrome and Infertility. Rev Bras Ginecol Obstet [internet]. 2019 [citado 18/03/2022];41(10): [aprox. 6 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31658490/

  24. Medina CA, Vera-Lastra EA, Saavedra O, Cruz-Dominguez MA, Amigo MD, Jara LJ. Damage index for antiphospholipid syndrome during long term follow-up: Correlation between organ damage accrual and quality of life. Lupus [internet]. 2021 [citado 18/03/2022];30(1): [aprox. 7 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33176566/

  25. Desnoyers M, Dufrost V, Wahl D, Zuily S. Helth- related quality of lifein antiphospholipidsyndrome: current knowledge and future perspectives. Curr Rheumatol Rep [internet]. 2020 [citado 18/03/2022];22(6): [aprox. 10 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32405870/

  26. Radin M, Grazietta Foddai S, Cecchi I, Roccatello D, Sciascia S. Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS). Eur J Intern Med [internet]. 2021 [citado 18/03/2022];92: [aprox. 4 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34330618/

  27. Georgopouloua SE, MacLennanc SJ, Ibrahima F, Coxb T. The relationship between social support and health-related quality of life in patients with antiphospholipid (hughes) syndrome. Modern Rheumatology [internet]. 2018 [citado 18/03/2022];28(1):[aprox. 9 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28463088/

  28. Martínez Delgado JF. Pérez de Alejo Rodríguez M, Abena Moore R, Navarro Moreno V. ¿Cómo vivir con lupus? Impacto de la labor educativa. Acta Médica del Centro [internet]. 2010 [citado 18/03/2022];4(4): [aprox. 7 p.]. Disponible en: http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/530

  29. Pérez-de-Alejo-Rodríguez M, Reyes-Hernández D, Pérez-Dueñas Y, Pérez-de-Alejo-Rodríguez A, Cruz-Vizcaíno B. El foro chat en la enseñanza del Síndrome antifosfolípidos. Experiencia novedosa en el aprendizaje de la clínica en el pregrado y el postgrado. EDUMECENTRO [Internet]. 2022 [citado 30/08/2022];14:e2443. Disponible en: http://www.revedumecentro.sld.cu/index.php/edumc/article/view/2443




2020     |     www.medigraphic.com